Does TORIPALIMAB Cause Immune-mediated myocarditis? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Immune-mediated myocarditis have been filed in association with TORIPALIMAB (LOQTORZI). This represents 0.8% of all adverse event reports for TORIPALIMAB.
11
Reports of Immune-mediated myocarditis with TORIPALIMAB
0.8%
of all TORIPALIMAB reports
4
Deaths
6
Hospitalizations
How Dangerous Is Immune-mediated myocarditis From TORIPALIMAB?
Of the 11 reports, 4 (36.4%) resulted in death, 6 (54.5%) required hospitalization, and 5 (45.5%) were considered life-threatening.
Is Immune-mediated myocarditis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TORIPALIMAB. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does TORIPALIMAB Cause?
Myelosuppression (590)
Off label use (276)
White blood cell count decreased (144)
Anaemia (67)
Hypothyroidism (67)
Neutrophil count decreased (67)
Nausea (60)
Rash (59)
Vomiting (58)
Platelet count decreased (53)
What Other Drugs Cause Immune-mediated myocarditis?
PEMBROLIZUMAB (599)
NIVOLUMAB (444)
IPILIMUMAB (248)
CARBOPLATIN (93)
DURVALUMAB (74)
LENVATINIB (66)
DOXORUBICIN (59)
PACLITAXEL (58)
PEMETREXED (43)
ATEZOLIZUMAB (37)
Which TORIPALIMAB Alternatives Have Lower Immune-mediated myocarditis Risk?
TORIPALIMAB vs TORSEMIDE
TORIPALIMAB vs TOVIAZ
TORIPALIMAB vs TOVORAFENIB
TORIPALIMAB vs TOZINAMERAN
TORIPALIMAB vs TRABECTEDIN